KR102916897B1 - D-세린의 중수소화 유사체 및 그의 용도 - Google Patents

D-세린의 중수소화 유사체 및 그의 용도

Info

Publication number
KR102916897B1
KR102916897B1 KR1020207017407A KR20207017407A KR102916897B1 KR 102916897 B1 KR102916897 B1 KR 102916897B1 KR 1020207017407 A KR1020207017407 A KR 1020207017407A KR 20207017407 A KR20207017407 A KR 20207017407A KR 102916897 B1 KR102916897 B1 KR 102916897B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutical composition
formula
delete delete
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207017407A
Other languages
English (en)
Korean (ko)
Other versions
KR20200103662A (ko
Inventor
다리오 돌러
크리스토퍼 엘. 브럼멜
줄리 에프. 리우
로저 디. 텅
Original Assignee
썬 파마슈티칼 인더스트리즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 썬 파마슈티칼 인더스트리즈 인코포레이티드 filed Critical 썬 파마슈티칼 인더스트리즈 인코포레이티드
Publication of KR20200103662A publication Critical patent/KR20200103662A/ko
Application granted granted Critical
Publication of KR102916897B1 publication Critical patent/KR102916897B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207017407A 2017-11-22 2018-11-21 D-세린의 중수소화 유사체 및 그의 용도 Active KR102916897B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762590109P 2017-11-22 2017-11-22
US62/590,109 2017-11-22
US201862636081P 2018-02-27 2018-02-27
US62/636,081 2018-02-27
US201862636427P 2018-02-28 2018-02-28
US62/636,427 2018-02-28
US201862755157P 2018-11-02 2018-11-02
US62/755,157 2018-11-02
PCT/US2018/062263 WO2019104179A1 (en) 2017-11-22 2018-11-21 Deuterated analogs of d-serine and uses thereof

Publications (2)

Publication Number Publication Date
KR20200103662A KR20200103662A (ko) 2020-09-02
KR102916897B1 true KR102916897B1 (ko) 2026-01-26

Family

ID=64755715

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207017407A Active KR102916897B1 (ko) 2017-11-22 2018-11-21 D-세린의 중수소화 유사체 및 그의 용도

Country Status (13)

Country Link
US (4) US20200368193A1 (https=)
EP (2) EP4560024A3 (https=)
JP (3) JP7518765B2 (https=)
KR (1) KR102916897B1 (https=)
CN (1) CN111491629A (https=)
AU (2) AU2018371784B2 (https=)
BR (1) BR112020010156A2 (https=)
CA (1) CA3082834A1 (https=)
IL (2) IL274585B2 (https=)
MX (1) MX2020005336A (https=)
PL (1) PL3713557T3 (https=)
TW (1) TWI886093B (https=)
WO (1) WO2019104179A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7518765B2 (ja) 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
RU2738873C2 (ru) * 2018-12-29 2020-12-17 Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата
WO2020206367A1 (en) * 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
WO2020243638A1 (en) * 2019-05-30 2020-12-03 Concert Pharmaceuticals, Inc. Methods of treatment with deuterated analogs of d-serine
WO2021127572A1 (en) * 2019-12-19 2021-06-24 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
PT871440E (pt) 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US5845286A (en) 1996-12-24 1998-12-01 Colizza; Vincent Date value reduction system
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
JP5266042B2 (ja) 2005-04-11 2013-08-21 エール ユニヴァーシティ 統合失調症前駆症の治療方法
EP1934201A1 (en) 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
EP3003378B1 (en) * 2013-05-28 2019-10-02 Sarah Herzog Memorial Hospital, Ezrat Nashim Association Use of nmdar agonists for the treatment of autoimmune-induced glutamatergic receptor dysfunction
WO2014205074A2 (en) 2013-06-18 2014-12-24 The Trustees Of Columbia University In The City Of New York Devices, compositions and methods for imaging with raman scattering
WO2015160470A2 (en) * 2014-03-20 2015-10-22 The Trustees Of Princeton University Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
WO2017210097A1 (en) 2016-06-02 2017-12-07 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
JP7518765B2 (ja) * 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
WO2020243650A1 (en) 2019-05-29 2020-12-03 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schizophr Res. 121(1-3): 125-130 (2010)*

Also Published As

Publication number Publication date
WO2019104179A1 (en) 2019-05-31
MX2020005336A (es) 2020-08-13
JP2023123476A (ja) 2023-09-05
BR112020010156A2 (pt) 2020-11-10
TW201924668A (zh) 2019-07-01
EP3713557B1 (en) 2025-03-12
TWI886093B (zh) 2025-06-11
KR20200103662A (ko) 2020-09-02
JP7518765B2 (ja) 2024-07-18
IL274585B1 (en) 2025-09-01
AU2025200345A1 (en) 2025-02-13
CA3082834A1 (en) 2019-05-31
JP2021504326A (ja) 2021-02-15
US20200368193A1 (en) 2020-11-26
US10668036B2 (en) 2020-06-02
US20250000830A1 (en) 2025-01-02
EP4560024A3 (en) 2025-08-20
IL274585A (en) 2020-06-30
IL274585B2 (en) 2026-01-01
EP4560024A2 (en) 2025-05-28
US20200390732A1 (en) 2020-12-17
AU2018371784A1 (en) 2020-05-28
CN111491629A (zh) 2020-08-04
PL3713557T3 (pl) 2025-09-22
IL322463A (en) 2025-09-01
WO2019104179A4 (en) 2019-08-01
JP7733058B2 (ja) 2025-09-02
JP2025138735A (ja) 2025-09-25
EP3713557A1 (en) 2020-09-30
AU2018371784B2 (en) 2024-10-17
US12029712B2 (en) 2024-07-09
US20190328692A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
KR102916897B1 (ko) D-세린의 중수소화 유사체 및 그의 용도
TW201827056A (zh) 用於預防及／或治療多囊性腎臟病之藥物
CA3091924A1 (en) Amide prodrugs of small molecule nuclear receptor modulators
EP4554929A1 (en) Preparation of stable psilocin salts, esters and conjugates and uses thereof
US20120071554A1 (en) Deuterated 2-propylpentanoic acid compounds
US20220313640A1 (en) Deuterated analogs of d-serine and uses thereof
EA050051B1 (ru) Дейтерированные аналоги d-серина и их применение
WO2022147189A1 (en) Varenicline prodrugs
US20220218641A1 (en) Methods of treatment with deuterated analogs of d-serine
EP4304655A1 (en) Fatty acid-bifunctional degrader conjugates and their methods of use
KR20250127049A (ko) 펜에틸아민 및 카티논 및 이의 입체이성질체 및 이의 전구체의 제조
EP4615443A1 (en) Crystalline carbazole derivative and methods of making thereof
BR112020022885B1 (pt) Processo para preparar um composto e composto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)